Effect of First-Line Chemotherapy Alone Versus First-Line Chemotherapy Plus Radiotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer in the IMRT Era: A Retrospective Cohort Study.
[BACKGROUND] The role of intensity-modulated radiotherapy (IMRT) and novel combination chemotherapy regimens in locally advanced pancreatic cancer (LAPC) remains unclear.
- p-value p = 0.038
- p-value p = 0.042
APA
Liu Z, Tian Y, et al. (2026). Effect of First-Line Chemotherapy Alone Versus First-Line Chemotherapy Plus Radiotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer in the IMRT Era: A Retrospective Cohort Study.. Cancer reports (Hoboken, N.J.), 9(4), e70531. https://doi.org/10.1002/cnr2.70531
MLA
Liu Z, et al.. "Effect of First-Line Chemotherapy Alone Versus First-Line Chemotherapy Plus Radiotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer in the IMRT Era: A Retrospective Cohort Study.." Cancer reports (Hoboken, N.J.), vol. 9, no. 4, 2026, pp. e70531.
PMID
41919345
Abstract
[BACKGROUND] The role of intensity-modulated radiotherapy (IMRT) and novel combination chemotherapy regimens in locally advanced pancreatic cancer (LAPC) remains unclear. In this study, we focused on comparing survival between first-line chemotherapy alone and first-line chemotherapy plus IMRT in patients with LAPC.
[METHODS] A total of 70 patients from Shandong Cancer Hospital and Institute were enrolled. The primary endpoint was progression-free survival (PFS). Survival outcomes were estimated by the Kaplan-Meier method and compared by the log-rank test, and the multivariate Cox proportional hazards model was used to estimate hazard ratios (HRs), 95% CIs, and independent prognostic factors.
[RESULTS] The median PFS was 10.0 months in the chemotherapy alone group and 14.0 months in the chemotherapy plus IMRT group (p = 0.465). Patients who received chemotherapy alone had a median OS of 12.0 versus 21.0 months for patients who received chemotherapy plus IMRT (p = 0.156). The chemotherapy alone group had a disease control rate (DCR) of 33.33% (6 of 18), while the chemotherapy plus IMRT group had a DCR of 61.54% (32 of 52) (p = 0.038). The multivariate Cox regression model was used to adjust for potential prognostic factors. Shorter PFS was observed in men (p = 0.042), and those with a high serum level of CA 19-9 (p = 0.047). Similarly, shorter OS was significantly associated with men (p = 0.010) and a high serum level of CA 19-9 (p = 0.020). Grade 3-4 fatigue or asthenia, decreased appetite, neutrophil count decreased, AST increased, and ALT increased were predominant in the chemotherapy alone group.
[CONCLUSION] The combination of first-line chemotherapy and IMRT improves the DCR rate (p = 0.038) and was well tolerated. However, first-line chemotherapy plus IMRT had no significant difference in PFS (p = 0.465) and OS (p = 0.156) compared with chemotherapy alone.
[METHODS] A total of 70 patients from Shandong Cancer Hospital and Institute were enrolled. The primary endpoint was progression-free survival (PFS). Survival outcomes were estimated by the Kaplan-Meier method and compared by the log-rank test, and the multivariate Cox proportional hazards model was used to estimate hazard ratios (HRs), 95% CIs, and independent prognostic factors.
[RESULTS] The median PFS was 10.0 months in the chemotherapy alone group and 14.0 months in the chemotherapy plus IMRT group (p = 0.465). Patients who received chemotherapy alone had a median OS of 12.0 versus 21.0 months for patients who received chemotherapy plus IMRT (p = 0.156). The chemotherapy alone group had a disease control rate (DCR) of 33.33% (6 of 18), while the chemotherapy plus IMRT group had a DCR of 61.54% (32 of 52) (p = 0.038). The multivariate Cox regression model was used to adjust for potential prognostic factors. Shorter PFS was observed in men (p = 0.042), and those with a high serum level of CA 19-9 (p = 0.047). Similarly, shorter OS was significantly associated with men (p = 0.010) and a high serum level of CA 19-9 (p = 0.020). Grade 3-4 fatigue or asthenia, decreased appetite, neutrophil count decreased, AST increased, and ALT increased were predominant in the chemotherapy alone group.
[CONCLUSION] The combination of first-line chemotherapy and IMRT improves the DCR rate (p = 0.038) and was well tolerated. However, first-line chemotherapy plus IMRT had no significant difference in PFS (p = 0.465) and OS (p = 0.156) compared with chemotherapy alone.
MeSH Terms
Humans; Pancreatic Neoplasms; Male; Female; Middle Aged; Radiotherapy, Intensity-Modulated; Retrospective Studies; Antineoplastic Combined Chemotherapy Protocols; Aged; Chemoradiotherapy; Prognosis; Adult; Progression-Free Survival; Survival Rate; Kaplan-Meier Estimate
같은 제1저자의 인용 많은 논문 (5)
- Tumor-derived ITIH2 activates PI3K\AKT pathway via THBS1 ubiquitination and promotes tumor angiogenesis in hepatocellular carcinoma.
- Repurposing disulfiram for ALDH-positive NSCLC: Network-based inhibition of EGFR, COX-2, and MAPK1.
- Lactate metabolism and protein lactylation in cancer.
- EP300 promotes hepatocellular carcinoma proliferation, migration and in vivo tumorigenicity revealed by integrated experimental and bioinformatic analyses.
- Extracellular Vesicle-Transferred ATP-Citrate Lyase Induces Monocyte Differentiation Toward Tumor-Associated Macrophages and Fuels Hepatocellular Carcinoma Progression.